GSK Therapeutic Summary Scorecard
Note: While the therapeutic Sotrovimab was developed with the support of Vir Biotechnology, this scorecard evaluates only GSK's practices.
**Sotrovimab is no longer FDA-approved to treat Covid-19 in areas with high frequency of the BA.2 Omicron subvariant.
A: Commitments and Accountability | Score | C: International cooperation | Score |
A1 The company publishes a global access plan for its product | ![]() | C1 The company commits to C-TAP or MPP | ![]() |
A2 The company commits to comply with human rights standards in relation to product development and marketing | ![]() | C2 The company commits to not enforcing the exclusive rights of Covid-19 related patents | ![]() |
C3 The company supplies to, or signs agreements with, the vaccines or therapeutics pillar of the ACT Accelerator | ![]() |
||
C4 The company agrees to license its Covid-19 medical products to other companies | ![]() |
||
E: Equality, non-discrimination & equity | Score | T: Transparency | Score |
E1 The company makes the active ingredient available on reasonable ground. [Only for therapeutics] | ![]() | T1 The company publishes its R&D costs. | ![]() |
E2 The company commits to full technology transfer to other manufacturers | ![]() | T2 The company publishes its profit margin. | ![]() |
E3 The company commits to non-profit, ‘fair’, or differential pricing | ![]() | T3 The company publishes the average and/or marginal costs of production. | ![]() |
E4 The company equitably distributes supplies globally. [Only applies to vaccines] | T4 The company publishes its production capacity. | ![]() |
|
E5 The company does not seek protection beyond the minimum criteria in TRIPS, or enforces TRIPS+ measures [where applicable] | ![]() | T5 The company publishes the public subsidies it received during product development and/or testing. | ![]() |
E6 The company agrees to waive exclusive rights in regulatory test data [where applicable]. | ![]() | T6 The company publishes the text of licensing agreements. | ![]() |
T7 The company registers its clinical trials in public repositories. | ![]() |
GSK Therapeutic Detailed Evaluation
Explore the results of PAF’s research into GSK’s behaviour. Each section is given an overall score; individual criteria are also scored (see icon following the criteria heading). Click on the ‘+’ sign next to each entry to expand and learn more.
A: Commitments and Accountability
Overall score:
A1 The company publishes a global access plan for its product
- GSK signed Gates Foundation ‘Commitments to Expanded Access for Covid-19 Diagnostics, Therapeutics and Vaccines’. States on website that GSK is committed to supporting global supply
- Score:
A2 The company commits to comply with human rights standards in relation to product development and marketing
- Position statement on human rights, supports UNGPs and other HR documents
- Believe that ‘governments are responsible for defining and enforcing a legal human rights framework’, but they ‘recognise that we have a role to play in upholding human rights and in addressing adverse human rights impacts where we are in a position to influence.’
- Score:
C: International Cooperation
Overall score:
C1 The company commits to C-TAP or MPP
- No commitment to a responsible licensing mechanism.
- Score:
C2 The company commits to not enforcing the exclusive rights of Covid-19 related patents
- No commitment not to enforce patents.
- Score:
C3 The company supplies to, or signs agreements with, the vaccines or therapeutics pillar of the ACT Accelerator
- No
- Score:
C4 The company agrees to license its Covid-19 medical products to other companies
- Yes, contract manufacturing deal with Samsung Biologics (South Korea). It is unclear whether this deal goes beyond fill-and-finish.
- Score:
E: Equality, non-discrimination & equity
Overall score:
E1 The company makes the active ingredient available on reasonable ground
- No evidence of this
- Score:
E2 The company commits to full technology transfer to other manufacturers
- Contract manufacturing deal with Samsung Biologics. The deal does not seem to include technology transfer.
- Score:
E3 The company commits to non-profit or ‘fair’ pricing
-
2100 USD per course in the US. Claims of ‘responsible pricing’ on website; but no evidence of fair or non-profit pricing
-
Score:
E4 The company equitably distributes supplies globally.
[Only applies to vaccines]E5 The company does not seek protection beyond the minimum criteria in TRIPS, or enforces TRIPS+ measures [where applicable]
- No evidence of enforcing TRIPS- or not enforcing TRIPS+
- Score:
E6 The company agrees to waive exclusive rights in regulatory test data [where applicable]
- No information.
- Score:
T: Transparency
Overall score:
T1 The company publishes its R&D costs
- Publishes overall R&D costs for 2021 but not specific to Sotrovimab
- Score:
T2 The company publishes its profit margin
-
GSK: £958m of sales for Sotrovimab, but does not mention a margin
- Score:
T3 The company publishes the average and/or marginal costs of production
- Does not publish the average and/or marginal costs of producing Sotrovimab.
- Score:
T4 The company publishes its production capacity
- 2 million doses in the first half of 2022.
- Score:
T5 The company publishes the public subsidies it received during product development and/or testing
Partially funded by Operation Warp Speed. This is not published on GSK’s website.
- Score:
T6 The company publishes the text of licensing agreements
- No licensing agreement texts are published.
- Score:
T7 The company registers its clinical trials in public repositories
- Registers clinical trials plus results in public clinical trial databases
- Score: